Global Diabetic Retinopathy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

List of Tables

The global demand for Diabetic Retinopathy Market is presumed to reach the market size of nearly USD 15.08 BN by 2030 from USD 8.61 BN in 2022 with a CAGR of 7.26% under the study period 2023 - 2030.

Diabetic retinopathy is an eye disease linked to diabetes, impacting the retina-the light-sensitive tissue at the back of the eye. It stands as a prominent cause of vision impairment among individuals with diabetes. The condition develops gradually as elevated levels of blood sugar associated with diabetes cause damage to the small blood vessels within the retina.

MARKET DYNAMICS

The diabetic retinopathy market is driven by several key factors, with the increasing global prevalence of diabetes being a primary contributor. As diabetes remains a significant health concern, the rising incidence contributes to a growing population at risk of diabetic retinopathy, propelling the demand for diagnostic and treatment solutions. The pivotal role of technological advancements in diagnostic tools and imaging techniques is evident in their contribution to enhancing early detection capabilities. The emphasis on regular eye screenings and the integration of telemedicine in screening programs further expands accessibility, particularly in underserved areas. Pharmaceutical innovations, including intravitreal injections and medications targeting diabetic macular edema, contribute to the market's development by offering effective management options. The heightened awareness among healthcare professionals and patients about the importance of eye health in diabetes management encourages increased screenings and early intervention.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of diabetic retinopathy. The growth and trends of diabetic retinopathy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the diabetic retinopathy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Proliferative Diabetic Retinopathy
Non-Proliferative Diabetic Retinopathy

By Management

Anti-VEGF
Intraocular Steroid Injection
Laser Surgery
Vitrectomy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Diabetic Retinopathy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Diabetic Retinopathy market include Bayer AG, ABBVIE INC., Novartis AG, Oxurion NV, Sirnaomics, Alimera Sciences, Ampio Pharmaceuticals Inc., BCNPeptides, Kowa Company Ltd., and Genentech, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112113274

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . DIABETIC RETINOPATHY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Management
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions
5.5 Non-proliferative Diabetic Retinopathy Historic and Forecast Sales by Regions

6 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY MANAGEMENT

6.1 Overview by Management
6.2 Historical and Forecast Data
6.3 Analysis by Management
6.4 Anti-VEGF Historic and Forecast Sales by Regions
6.5 Intraocular Steroid Injection Historic and Forecast Sales by Regions
6.6 Laser Surgery Historic and Forecast Sales by Regions
6.7 Vitrectomy Historic and Forecast Sales by Regions

7 . GLOBAL DIABETIC RETINOPATHY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE DIABETIC RETINOPATHY COMPANIES

8.1. Diabetic Retinopathy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF DIABETIC RETINOPATHY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Bayer AG
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. ABBVIE INC.
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Novartis AG
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Oxurion NV
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Sirnaomics
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Alimera Sciences
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Ampio Pharmaceuticals Inc.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. BCNPeptides
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Kowa Company Ltd.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Genentech Inc.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies